PROMINENT - Cancer Grand Challenges

Scientific projects

A world-class team of researchers co-led by Dr. Nuria Lopez-Bigas has been selected to receive a $25M Cancer Grand Challenges Award to investigate the very early stages of cancer development. Co-founded by the Asociación Española Contra el Cáncer (AECC), Cancer Research UK, and the US National Cancer Institute, Cancer Grand Challenges is a global funding platform that supports a community of diverse teams across the world to come together, think differently, and tackle some of the toughest issues in cancer research.

The Cancer Grand Challenges PROMINENT team, co-led by Allan Balmain (University of California, San Francisco) and Paul Brennan (International Agency for Research on Cancer (IARC)), will be working to answer questions about the very early stages of tumour development—what keeps healthy cells healthy and what triggers a cell to become cancerous? The answers are likely to be more complex than we once thought, and the team will build on recent findings that suggest cells can remain seemingly ‘normal’ despite carrying cancer-driving mutations in their DNA. With this information, the team will build a ‘roadmap’ of early cancer stages in the hope of finding new, informed ways to prevent the development of cancer

The PROMINENT team brings together advocates and scientists with expertise in epidemiology, genetics, imaging, and other fields across five institutions in Spain, France, and the US. Focused on finding new approaches to prevent cancer development, the team aims to reduce the burden of this disease globally.




For more information:

Thank you!

We would like to thank all the people and institutions who have made 2022 an exceptional year. Thanks to your contributions, our science is bringing about biomedical breakthroughs that have an increasing impact on people's lives. We would also like to thank all the people and organisations who have joined the Metastasis Challenge.

Every donation, every event, every legacy helps us get one step closer to our goal of stopping metastasis.